Operating Income (Loss) in USD of C4 Therapeutics, Inc. from Q3 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
C4 Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q3 2019 to Q3 2025.
  • C4 Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$34.4M, a 21.8% decline year-over-year.
  • C4 Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$130M, a 8.76% decline year-over-year.
  • C4 Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$120M, a 14% increase from 2023.
  • C4 Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$139M, a 7.33% decline from 2022.
  • C4 Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$130M, a 57.7% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

C4 Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$130M -$34.4M -$6.17M -21.8% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 -$124M -$28.5M -$7.06M -32.9% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 -$117M -$29.2M +$3.06M +9.48% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 -$120M -$37.7M -$282K -0.75% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 -$119M -$28.2M -$436K -1.57% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 -$119M -$21.4M +$16.1M +42.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 -$135M -$32.2M +$4.01M +11.1% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 -$139M -$37.4M +$866K +2.26% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 -$140M -$27.8M +$4.68M +14.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 -$145M -$37.6M -$10.2M -37.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$134M -$36.2M -$4.86M -15.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$130M -$38.3M -$23M -151% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 -$106M -$32.5M -$8.23M -33.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$98.3M -$27.4M -$5.27M -23.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$93M -$31.4M -$10.9M -53% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$82.1M -$15.3M +$3.65M +19.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-23
Q3 2021 -$85.8M -$24.3M -$5.91M -32.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$79.9M -$22.1M -$11.3M -104% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$68.6M -$20.5M -$8.17M -66.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$60.4M -$18.9M Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 -$18.3M -$8.35M -83.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$10.9M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$12.3M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q3 2019 -$10M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12

C4 Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$120M +$19.4M +14% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 -$139M -$9.5M -7.33% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 -$130M -$47.4M -57.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 -$82.1M -$21.7M -35.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-23
2020 -$60.4M -$25M -70.5% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-24
2019 -$35.5M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.